Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02477696 · ClinicalTrials.gov registry record · Phase 3

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

A Phase 3 study of Chronic Lymphocytic Leukemia, sponsored by Acerta Pharma.

Active
Registry status
Phase 3
Development phase
533
Enrollment target
20
Study locations

NCT02477696: Active Phase 3 study of Chronic Lymphocytic Leukemia, sponsored by Acerta Pharma.

NCT02477696 is a Phase 3 study of Chronic Lymphocytic Leukemia that is active but no longer recruiting, run by Acerta Pharma. The registered enrollment target is 533 participants, above the 179-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (198% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02477696, a Phase 3 study of Chronic Lymphocytic Leukemia, is active but no longer recruiting, sponsored by Acerta Pharma.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
533 participants
Enrollment target
20
Study locations

Study Summary

This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic lymphocytic leukemia.

Primary Outcome

The PFS is defined as the time from date of randomization to the date of first IRC-assessed PD or death due to any cause, whichever occurred first. PD (per International Workshop on Chronic Lymphocytic Leukemia \[iwCLL\] 2008 criteria): Lymphocytes \>= 50% increase over baseline, or \>= 50% increase in lymphadenopathy/hepatomegaly/splenomegaly, or \>= 50% platelets or \> 2 g/dL hemoglobin decreases from baseline secondary to chronic lymphocytic leukemia (CLL). The PFS is assessed using the Kapla

Conditions Studied

Chronic Lymphocytic Leukemia

Interventions

  • DRUG Acalabrutinib
  • DRUG Ibrutinib

Study Locations (20)

California

  • Research Site - Anaheim
  • Research Site - Berkeley
  • Research Site - Duarte
  • Research Site - La Jolla
  • Research Site - Los Angeles
  • Research Site - Palo Alto
  • Research Site - Santa Rosa

Florida

  • Research Site - Jacksonville
  • Research Site - Tampa

Illinois

  • Research Site - Harvey
  • Research Site - Peoria

Minnesota

  • Research Site - Minneapolis
  • Research Site - Rochester

New York

  • Research Site - Lake Success
  • Research Site - New Hyde Park

Arizona

  • Research Site - Phoenix

Georgia

  • Research Site - Athens

Kansas

  • Research Site - Wichita

Trial Details

FieldValue
Enrollment Target 533 participants
Start Date 2015-07-28
Est. Completion 2028-01-03
Phase Phase 3
Acerta Pharma

38 total trials

What the registry record for NCT02477696 still lists

NCT02477696 is an interventional study that assigns participants to a tested intervention. The registered 533 participants enrollment target is mid-sized for trials with a published cap, above the 179-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (198% higher).

The record links to 1 condition, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Acalabrutinib is the first listed.

NCT02477696 names 20 study sites across 10 states, led by California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT02477696 about?

NCT02477696 is a clinical study titled "Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)". This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic lymphocytic leukemia.

What is the current status of trial NCT02477696?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 533 participants. The study started on 2015-07-28. Estimated completion is 2028-01-03.

What conditions does trial NCT02477696 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia.

What interventions are being tested in trial NCT02477696?

The interventions under investigation include: Acalabrutinib (DRUG), Ibrutinib (DRUG).

Who is sponsoring clinical trial NCT02477696?

This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02477696 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02477696's enrollment target sits among peer trials

533 19th of 187 higher than 169 of 187 other Chronic Lymphocytic Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04910685 · 534 participants · Phase 2

    (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

  • NCT06128551 · 534 participants · Phase 1

    Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • NCT05793151 · 532 participants · NA

    Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy

  • NCT06378866 · 532 participants · Phase 2

    Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02477696, the US trial registry maintained by the National Library of Medicine. NCT02477696 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.